Clinical trials: Carcinoma of Lung
Depression, Anxiety
Validation of the Russian and Kazakh Versions of the Beck Depression Inventory and Beck Anxiety Inventory
Depression and anxiety in female patients with cancer are serious comorbidities that affect the quality of life for patients and their survival rates as they have poorer health outcomes.
- Conditions
- Depression, Anxiety, Breast Cancer, Ovarian Cancer
- Trial name
- NCT04630327
- Testing
- Beck Depression Inventory-21 (diagnostic survey), Beck Anxiety Inventory, Interview using The International Classification of Diseases in tenth edition (ICD-10) criteria
- Where
- 2 sites in Kazakhstan
- Volunteers
- 226 people
- Sponsor
- Kazakh Medical University of Continuing Education
Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain
Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer
This phase II trial tests how well cemiplimab works in treating patients with PD-L1 >= 50% non-small cell lung cancer (NSCLC) that has spread from where it first started (primary site) to the brain (metastases).
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT05840770
- Testing
- Biospecimen Collection, Cemiplimab, Computed Tomography
- Sponsor
- City of Hope Medical Center
Non-Small Cell Lung Cancer
Role of PET CT in Determining Target Volumes in Radiation Therapy for Lung Cancer
Radiation therapy is an important part of the treatment for lung cancer when treatment intent is for cure. Radiation is a local modality of treatment, that is, it only treats the area that the radiation can target.
- Trial name
- NCT00221169
- Testing
- Surgical resection
- Where
- 2 sites in Canada
- Volunteers
- 31 people
- Sponsor
- Toronto Sunnybrook Regional Cancer Centre
Muscle-Invasive Bladder Carcinoma, Gastroesophageal Adenocarcinoma
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
This is a phase 1 clinical trial to evaluate the safety, feasibility and immunogenicity of a personalized cancer vaccine strategy in patients with solid tumors and molecular residual disease.
- Conditions
- Muscle-Invasive Bladder Carcinoma, Gastroesophageal Adenocarcinoma, Melanoma, Non-small Cell Lung Cancer
- Trial name
- NCT06529822
- Testing
- Synthetic long peptide personalized cancer vaccine, Poly ICLC, Signatera or Altera testing
- Where
- 3 sites in United States
- Volunteers
- 64 people
- Sponsor
- Washington University School of Medicine
Non-small Cell Lung Cancer (NSCLC)
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without…
- Trial name
- TROPION-Lung17 (NCT07291037)
- Testing
- Datopotamab deruxtecan (Dato-DXd), Docetaxel
- Where
- 206 sites in United States, Australia and 19 more
- Volunteers
- 400 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).
This study is an open label study followed by a randomised, double-blind, placebo-controlled, parallel group and an extension study to investigate the safety and efficacy of GB1211 (a galectin-3 inhibitor) in combination with…
- Trial name
- NCT05240131
- Testing
- GB1211, Atezolizumab
- Where
- 5 sites in France, Poland and 1 more
- Volunteers
- 88 people
- Sponsor
- Galecto Biotech AB
Malignant Pulmonary Nodules, Lung Cancer
Evaluation of the Safety and Efficacy of a Wideband Electric Pulse Tumor Ablation System for Malignant Pulmonary Nodules
To evaluate the safety and efficacy of the wideband electric pulse tumor ablation system, for the treatment of malignant pulmonary nodules.
- Trial name
- NCT07638228
- Testing
- wideband electric pulse tumor ablation system treatment
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Sir Run Run Shaw Hospital
Malignant Pleural Effusions, NSCLC Stage IV
A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC
This is a phase 1/phase 2, multicenter, open-label study to evaluate the safety, tolerability, PK, PD, immunogenicity and preliminary efficacy of M701 in patients with treatment of malignant pleural effusions caused by NSCLC.
- Trial name
- NCT05543330
- Testing
- M701 pleural infusion, Pleural drainage, Cisplatin pleural infusion
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Wuhan YZY Biopharma Co., Ltd.
Lung Adenocarcinoma, Cancer-related Fatigue
Chaigui Jieyu Qufa Decoction for CRF in Driver Gene-negative Lung Adenocarcinoma Trial
The goal of this [clinical trial] is to [evaluate whether Chaiyu Jieyu Qufa Decoction can improve cancer-related fatigue and assess its safety] in [patients aged 18-80 years with untreated lung adenocarcinoma complicated with…
- Conditions
- Lung Adenocarcinoma, Cancer-related Fatigue, Liver Depression and Spleen Deficiency Syndrome (Traditional Chinese Medicine)
- Trial name
- CJQD-CRF (NCT07890051)
- Testing
- Chai-Gui Jieyu Qufa Granules
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Carcinoma, Non-Small-Cell Lung, Epidermal Growth Factor Receptor
Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC
Leptomeningeal metastasis (LM) is a complication of advanced non-small cell lung cancer (NSCLC). The incidence of LM in NSCLC patients is around 3-5 %, reaching 9.4 % of those with an epidermal growth factor receptor (EGFR)…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Epidermal Growth Factor Receptor, Leptomeningeal Metastasis
- Trial name
- NCT05805631
- Testing
- Pemetrexed
- Where
- Taiwan
- Volunteers
- 23 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
STAGE IIIB OR IV NON-SMALL CELL LUNG CANCER
A Phase II Study of Velcade® in Patients Stage IIIB OR IV Non-Small Cell Lung Cancer
The purpose of this study is to determine whether Bortezomib is effective in the treatment of patients with non-small-cell lung cancer who have not received any prior chemotherapy regimen for advanced disease.
- Trial name
- NCT00346645
- Testing
- Bortezomid (VELCADE®)
- Where
- France
- Volunteers
- 46 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Extensive-stage Small Cell Lung Cancer, Lung Cancer
Apatinib and Etoposide as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line Chemotherapy
Although fist-line therapy with Cisplatin and etoposide(EP)or Carboplatin and etoposide(CE) has been given, patients with extensive small cell lung cancer(ED-SCLC) still relapse and the 2-year survival is extremely low.
- Trial name
- NCT03135977
- Testing
- Apatinib, Etoposide
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Effect of Symptom Management on Inflammation and Survival in Metastatic Lung Cancer
There is a growing body of evidence that implicates inflammation as a mechanism of disease progression and reduced survival in patients with advanced cancer.
- Trial name
- NCT02271581
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Leo W. Jenkins Cancer Center
Small Cell Lung Cancer
A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer
The purpose of this study is to assess the safety and efficacy of rovalpituzumab tesirine administered in combination with nivolumab or nivolumab and ipilimumab in participants with extensive-stage small cell lung cancer (SCLC).
- Trial name
- NCT03026166
- Testing
- Ipilimumab, Nivolumab, Rovalpituzumab tesirine
- Where
- 35 sites in United States, France and 3 more
- Volunteers
- 42 people
- Sponsor
- AbbVie
Locally Advanced Non-Small Cell Lung Cancer
A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy
This is a phase II, open-Label, multi-centre study to determine the efficacy and safety of Camrelizumab plus apatinib in participants with unresectable Stage III Non-Small Cell Lung Cancer (NSCLC), who have not progressed…
- Trial name
- NCT04749394
- Testing
- Camrelizumab, PD-1 monoclonal antibody, Apatinib, VEGFR2 antibody
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Chinese Academy of Medical Sciences
Non Small Cell Lung Cancer, Esophageal Cancer
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery.
- Conditions
- Non Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- NCT03551951
- Testing
- Test for circulating tumor cells, DNA alterations
- Where
- United States
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Healthy Volunteer
Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers
This is a Phase 1, open-label, 2-period fixed sequence design to evaluate the interaction of AZD9291 with omeprazole in approximately 50 healthy, adult male volunteers.
- Trial name
- NCT02224053
- Testing
- Pharmacokinetic sampling - AZD9291, AZD9291 tablet dosing, Omeprazole tablet dosing
- Where
- 2 sites in United States
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Malignant Pleural Mesothelioma
Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma Patients
This is a multicenter retrospective analysis .The aim of the present study is to investigate the molecular predictors of vinorelbine response in tumor samples of a series of MPM patients and evaluate the possible impact on…
- Trial name
- NCT01865045
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Armando Santoro, MD
Small Cell Lung Carcinoma
Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer
The purpose of this Managed Access Program (MAP) Cohort Treatment Plan is to provide guidance to the Physician for the treatment and monitoring of eligible patients diagnosed with BRAF V600E/K activating mutation-positive…
- Trial name
- NCT04507919
- Testing
- Dabrafenib, Trametininb
- Sponsor
- Novartis Pharmaceuticals
Solid Tumor, Non-Small Cell Lung Cancer Metastatic
Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK
This study is aimed to determine the maximum tolerated dose of ensartinib, an oral ALK inhibitor in Chinese patients with ALK-positive non-small cell lung cancer
- Trial name
- NCT02959619
- Testing
- Ensartinib
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.